News
TipRanks on MSN2d
Merck Stock (MRK) Bulls Cheer $10Bn Verona Pharma GambleMerck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...
Zacks Investment Research on MSN4h
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.
Zacks.com on MSN3d
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why ...
Contacts. Media: Patrick Ryan, 973-275-7075 Melissa Moody, 215-407-3536 Investor: Peter Dannenbaum, 908-740-1037 Raychel Kruper, 908-740-2107 ...
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback